Core Insights - Nanmo Bio's stock increased by 0.57% on September 25, with a trading volume of 54.01 million yuan, indicating a stable market performance [1] - The company reported a net financing outflow of 1.55 million yuan on the same day, with a total financing balance of 105 million yuan, representing 2.56% of its market capitalization [1] - For the first half of 2025, Nanmo Bio achieved a revenue of 196 million yuan, reflecting a year-on-year growth of 10.69%, and a net profit of 18.17 million yuan, marking a significant increase of 298.69% [2] Financing and Shareholding - As of September 25, Nanmo Bio's financing buy-in was 4.25 million yuan, while the financing repayment was 5.80 million yuan, indicating a high level of trading activity [1] - The company has a total of 6,522 shareholders as of June 30, 2025, which is an increase of 4.32% from the previous period, with an average of 11,953 circulating shares per shareholder, up by 51.32% [2] - The company has distributed a total of 30.04 million yuan in dividends since its A-share listing, with 10.00 million yuan distributed in the last three years [3] Business Overview - Nanmo Bio specializes in the research, production, and sales of genetically modified animal models, with its main revenue sources being standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), and customized models (9.34%) [1] - The company is headquartered in Shanghai and was established on September 20, 2000, with its stock listed on December 28, 2021 [1]

智通财经记者 | 李科文 智通财经编辑 | 谢欣 在上一届董事会（第三届）中，南模生物的席位分散，共设9席，其中独立董事3名，非独立董事6名。具体名单为：董 事费俭、王明俊、周热情、曾学波、苏跃星、成旭光，以及独立董事任海峙、单飞跃、邵正中。其中，周热情代表股东 上海科技创业投资；曾学波代表深圳前海海润荣丰投资；苏跃星代表康君投资管理；成旭光代表上海张江集体资产投 资。 南模生物各方股东在董事会的博弈暂时达成平衡。 9月24日，南模生物公布新一届董事会换届选举结果。由控股股东上海砥石提名的费俭、王明俊、孙瑞林、房永生当选 非独立董事；上海国资背景的上海科技创业投资代表杨利华当选非独立董事；新晋二股东、同样为上海国资背景的海望 合纵与浦东新产业提名的应涛涛亦当选非独立董事。 在独立董事方面，上海砥石提名的尹向东、郑依彤成功当选；上海科技创业投资代表于谦龙和海望合纵、浦东新产业提 名的许庆同样进入董事会。 表面上看，这是南模生物三大主要股东力量角逐的结果。但背后其实是四方股东在博弈。因为，在控股上海砥石内部， 董事长兼创始人费俭与总经理王明俊间同样存在分歧。 9月25日，智通财经致电南模生物董秘办，询问此前董事长 ...

Core Viewpoint - The recent shareholder meeting of Nanmo Biology (688265.SH) raised concerns in the market as several key proposals were not approved, indicating potential internal conflicts and governance issues within the company [1][3]. Shareholder Meeting Outcomes - On September 23, 2025, Nanmo Biology held its second extraordinary shareholder meeting, reviewing 11 proposals, of which 5 were rejected, including those related to the company's three-year development plan and management stability [1][4]. - Only one of the additional six temporary proposals put forth by the Shanghai Pudong State-owned Assets Supervision and Administration Commission was approved, specifically regarding the purchase of liability insurance for directors and senior management [4][5]. Shareholding Structure - The shareholding structure of Nanmo Biology has become more concentrated, with a new shareholder, Suzhou Haiwang Hezhong No. 1 Equity Investment Partnership, acquiring 8.68 million shares, representing 11.13% of the total share capital [1][2]. - Haiwang Hezhong and Shanghai Pudong New Industry Investment Co., which holds 7.37% of the shares, are acting in concert, collectively owning 18.50% of the company [2]. Board Composition - The newly elected board consists of 11 directors, with 6 non-independent directors nominated by the controlling shareholder, and 4 independent directors, including one nominated by Haiwang Hezhong [5]. - The board's composition reflects a division among major shareholders, with the controlling shareholder's camp not being entirely unified, as evidenced by the recent dissolution of the agreement between key figures Fei Jian and Wang Mingjun [3][5].

Market Overview - On September 24, the medical services sector declined by 2.01%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Individual Stock Performance - Bid Medicine (688073) saw a closing price of 74.63, with a gain of 5.74% and a trading volume of 13,300 hands, totaling a transaction value of 98.38 million [1] - Tiger Medical (300347) closed at 61.00, up 5.54%, with a trading volume of 150,500 hands and a transaction value of 908 million [1] - Guangzheng Eye Hospital (002524) closed at 4.23, up 4.44%, with a trading volume of 189,200 hands and a transaction value of 78.72 million [1] - Nanmo Biology (688265) closed at 52.35, down 1.75%, with a trading volume of 11,300 hands and a transaction value of 59.06 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 318 million from institutional investors and 117 million from retail investors, while retail investors saw a net inflow of 434 million [2][3] - Tiger Medical (300347) had a net inflow of 10.8 million from institutional investors but a net outflow of 9.19 million from retail investors [3] - Eye Care (300015) recorded a net inflow of 37.33 million from institutional investors, while retail investors had a net outflow of 41.60 million [3]

Core Points - The company, Nanmo Biology, announced the election of Wang Jinjing as the employee representative director for its fourth board of directors during a recent employee representative meeting [2] Summary by Category - **Corporate Governance** - The employee representative meeting approved the proposal to elect Wang Jinjing as the employee representative director [2]

证券代码：688265 证券简称：南模生物 公告编号：2025-061 上海南方模式生物科技股份有限公司 关于选举第四届董事会职工代表董事的公告 根据《公司章程》的规定，公司董事会由 11 名董事组成（包括 4 名独立董 事、1 名职工代表董事），其中 10 名股东代表董事由公司股东大会选举产生，1 名职工代表董事由公司职工通过职工代表大会民主选举产生。本次职工代表大会 选举产生的职工代表董事，将与公司 2025 年第二次临时股东大会选举产生的股 东代表董事共同组成公司第四届董事会，任期与公司第四届董事会一致。 特此公告。 上海南方模式生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"或"南模生物"） 于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会审议通过了《关于调整董 事会席位、取消监事会并修订<公司章程>的议案》，根据修订后的《上海南方模 式生物科技股份有限公司章程》（2025 年 5 月修订）（以下简称"《公司章程》"） 规 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-060 上海南方模式生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：有 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 58,958,601 | | 普通股股东所持有表决权数量 | 58,958,601 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 77.9698 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 77.9698 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长费俭先生主持，采取现场投票和网 （ ...

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：上海南方模式生物科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共和国 公司法》（以下简称"《公司法》"）和中国证券监督管理委员会（以下简称"中国 证监会"）《上市公司股东会规则》等法律、法规、规章和其他规范性文件以及《上 海南方模式生物科技股份有限公司章程》（以下简称"《公司章程》"）的要求，上 海市锦天城律师事务所（以下简称"本所"）接受上海南方模式生物科技股份有限公 司（以下简称"南模生物"或"公司"）的委托，指派本所律师参加南模生物 2025 年第 二次临时股东大会（以下简称"本次股东大会"），就本次股东大会的有关事宜并出 具 ...

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

Group 1 - The core point of the article highlights the performance and financial metrics of Nanmo Biotechnology, which saw a stock price increase of 5.71% to 57.24 CNY per share, with a total market capitalization of 4.463 billion CNY [1] - Nanmo Biotechnology specializes in the research, production, and sales of genetically modified animal models, with its main revenue sources being standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and other services (0.91%) [1] - The company is located in Shanghai and was established on September 20, 2000, with its listing date on December 28, 2021 [1] Group 2 - Among the top shareholders of Nanmo Biotechnology, the Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) reduced its holdings by 150,000 shares in the second quarter, now holding 800,000 shares, which represents 1.03% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 2.074 billion CNY and has achieved a year-to-date return of 20.36%, ranking 4289 out of 8244 in its category [2] - The fund has delivered a one-year return of 44.25%, ranking 3678 out of 8066, and a cumulative return of 190.8% since its inception on December 25, 2014 [2]